Navigation Links
Ikaria(R) Names New Chairman
Date:10/19/2009

CLINTON, N.J., Oct. 19 /PRNewswire/ -- Ikaria Holdings, Inc. today announced that Board Chairman David E. Shaw is retiring from the board. Current Ikaria CEO Daniel Tasse has been named Chairman of the Board, succeeding Shaw, who has served as Chairman since 2007.

Shaw was a founding investor and director in Ikaria, Inc., a biotechnology company that was formed in 2005, and was instrumental in combining it with INO Therapeutics in 2007 to form Ikaria Holdings, Inc. The transaction, valued at $670M, was led by New Mountain Capital and included ARCH Venture Partners and Venrock. Shaw served as founding CEO until Tasse's appointment as Director, President and CEO in January 2008. He is active in other private and public companies, and serves as Managing Partner of Black Point Group and a partner at Venrock.

"Ikaria exists and flourishes today because of the direction David Shaw established for the company from the beginning, including its focus on critical care and the formation of a strong and experienced management team," said Daniel Tasse, Chairman and CEO of Ikaria. "We thank David for his vision and leadership and wish him continued success in his future endeavors."

Prior to joining Ikaria in January 2008, Tasse served as General Manager of the $2 billion Pharmaceuticals & Technologies business of Baxter International, Inc., a division which was created by integrating the company's Anesthesia, Critical Care and BioPharma Solutions units. Prior to his tenure at Baxter International, Tasse held management positions at GlaxoSmithKline and Upjohn. He has a B.Sci. in Biochemistry from the University of Montreal.

About Ikaria Holdings, Inc.

Ikaria Holdings, Inc. is a biotherapeutics company whose acute care products and therapies address the significant unmet needs of critically ill patients. The company's lead product, INOmax® (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns, and also is marketed in Canada, Europe, Latin America, Australia, Japan and Mexico. Ikaria is engaged in new and ongoing clinical development of INOmax, carbon monoxide for inhalation and hydrogen sulfide. Ikaria also acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. The company also recently acquired the exclusive worldwide licenses to BL-1040, a potential breakthrough treatment for preventing pathological cardiac remodeling following acute myocardial infarction, as well as to a portfolio of investigational compounds focused on vascular leakage for a range of critical care conditions, such as acute liver and kidney injury. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. Please visit www.ikaria.com.

SOURCE Ikaria Holdings, Inc.


'/>"/>
SOURCE Ikaria Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
2. Ikaria(R) to Present at 27th Annual JPMorgan Healthcare Conference
3. IKARIA(R) to In-License BioLineRxs BL-1040
4. KGI Names Kerry Howell Vice President for Advancement
5. Vical Names Andrew de Guttadauro Vice President, Corporate Development
6. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
7. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
8. CryoLife Names Philip Theodore as Vice President, General Counsel
9. Genstar Names Michael Hurt to Its Strategic Advisory Board
10. PPD Names Daniel Darazsdi as Chief Financial Officer
11. Society of Laproendoscopic Surgeons Names Starion Instruments 2007 Innovator of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... A ... in Hong Kong. , Nerium International is proud to introduce its Age-Defying Night ... Cream, NeriumAD™ Formula to consumers across Hong Kong. The luxury skincare products contain ...
(Date:2/17/2017)... ... ... Academy of Model Aeronautics (AMA), the nation’s leading voice ... systems (UAS), are launching a joint program to promote safe and responsible drone ... efforts. , AMA and DJI will collaborate on other potential opportunities to mutually ...
(Date:2/16/2017)... GREENWICH, Conn. , Feb. 16, 2017 ... on venture growth investments in biotechnology and medical ... Richardson , M.D. to Managing Director. ... He is a board observer at InfaCare Pharmaceutical ... investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence Pharmaceuticals ...
(Date:2/16/2017)...   Biostage, Inc. (Nasdaq: BSTG ... bioengineered organ implants to treat cancers and other life-threatening ... the closing on February 15, 2017 of its previously ... and warrants to purchase 20,000,000 shares of common stock, ... was priced at $0.40 per share of common stock, ...
Breaking Biology Technology:
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
Breaking Biology News(10 mins):